149
Participants
Start Date
May 31, 2014
Primary Completion Date
February 29, 2016
Study Completion Date
January 31, 2017
Ruxolitinib
"5 mg tablets to be administered by mouth~Ruxolitinib 15 mg BID (starting dose)"
Capecitabine
Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
Placebo
5 mg matching placebo tablets to be administered by mouth
Birmingham
Chandler
Sedona
La Jolla
Los Angeles
Oxnard
San Diego
San Francisco
Santa Monica
Aurora
Denver
New Haven
Washington D.C.
Fort Myers
Hialeah
Miami
Plantation
St. Petersburg
Tampa
Atlanta
Marietta
Savannah
Chicago
Quincy
Springfield
Urbana
Ames
Wichita
Louisville
Baton Rouge
Baltimore
Detroit
Kalamazoo
Duluth
Minneapolis
Kansas City
St Louis
Grand Island
Omaha
Camden
Hackensack
Farmington
Albany
Johnson City
New York
The Bronx
Goldsboro
Pinehurst
Canton
Cincinnati
Cleveland
Columbus
Middletown
Portland
Bethlehem
Philadelphia
Pittsburgh
Charleston
Greenville
Chattanooga
Germantown
Nashville
Arlington
Bedford
Dallas
El Paso
Fort Worth
Houston
McAllen
Plano
Tyler
Ogden
Salt Lake City
Fairfax
Norfolk
Richmond
Salem
Seattle
Green Bay
Milwaukee
La Roche-sur-Yon
Paris
Alba
Fano
Foggia
Lecco
Milan
Naples
Pontedera
Roma
Saronno
Lisbon
A Coruña
Barcelona
Jaén
Lleida
Madrid
Cardiff
Glasgow
Kingston upon Thames
London
Nottingham
Sutton
Taunton
Truro
Yeovil
Lead Sponsor
Incyte Corporation
INDUSTRY